The Origins of LATISSE® the story behind the discovery
It's remarkable how one great product can lead to another. Such was the case with LATISSE®.

Allergan, a leader and pioneer in eye care, dermatology and medical aesthetics, has introduced the world to a range of products, including LATISSE®, the first and only FDA-approved prescription treatment for inadequate or not enough eyelashes, growing them longer, fuller and darker. But its origin wasn't completely new.

Back in 2001, Allergan developed a medicated eye drop used to treat ocular hypertension. In addition to successfully lowering eye pressure (the only treatable risk factor for glaucoma), many patients using this medication experienced a side effect — they began to grow longer, fuller and darker lashes.

This led Allergan to begin its study of this medication’s active ingredient, bimatoprost ophthalmic solution 0.03%, for the sole purpose of generating lash growth. After conducting a clinical trial on safety and efficacy for 4 months on 278 patients, LATISSE® earned its FDA approval in December 2008. Since then, Allergan has sold approximately 1.5 million bottles of LATISSE® solution.

PRINT PAGE
SHARE THIS
SIGN UP
LATISSE® Indication
LATISSE® solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.
Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.
LATISSE® Important Safety Information
If you are using, or have used, prescription products for any eye pressure problems, only use LATISSE® under close doctor care. Although not seen in LATISSE® clinical studies, may cause increased brown pigmentation of the colored part of the eye which is likely permanent. Eyelid skin darkening may occur which may be reversible. Only apply at the base of the upper eyelashes. DO NOT APPLY to the lower eyelid. Hair growth may occur in other skin areas that LATISSE® solution frequently touches. If you develop or experience any eye problems or have eye surgery, consult your doctor immediately about continued use of LATISSE®. The most common side effects after using LATISSE® solution are itchy eyes and/or eye redness. If discontinued, lashes will gradually return to their previous appearance.
Please click here for full LATISSE® Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
BOTOX® Cosmetic Important Information
Indication
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in people 18-65 years of age for a short period of time (temporary).
IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.

  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice (dysphonia), trouble saying words clearly (dysarthria), loss of bladder control, trouble breathing, trouble swallowing.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines.

The dose of BOTOX® Cosmetic is not the same as, or comparable to, another botulinum toxin product.

Serious and/or immediate allergic reactions have been reported. These reactions include itchy rash, swelling, and shortness of breath. Tell your doctor or get medical help right away if you experience any such symptoms, further injection of BOTOX® Cosmetic should be discontinued.

Do not take BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® or Dysport®; have a skin infection at the planned injection site.

Tell your doctor about all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], myasthenia gravis or Lambert-Eaton syndrome as you may be at increased risk of serious side effects including severe dysphagia (difficulty swallowing) and respiratory compromise (difficulty breathing) from typical doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including if you have: plans to have surgery; had surgery on your face; weakness of forehead muscles, such as trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (It is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to breastfeed (It is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal products.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, or vision problems. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Other side effects of BOTOX® Cosmetic include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes.
For more information refer to the Medication Guide or talk with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see BOTOX® Cosmetic full Product Information, including Medication Guide.

Note: This document is provided in Adobe® Reader® format (PDF). To view PDF documents, you must have the Adobe® Reader® software installed on your computer. If you do not have Adobe® Reader®, download it from the Adobe Website.

ALLERGAN © 2010 Allergan, Inc. Irvine, CA 92612. ® marks owned by Allergan, Inc.
Juvéderm® mark owned by Allergan Industrie SAS.
Myobloc® is a registered trademark of Solstice Neurosciences, Inc.
Dysport® is a registered trademark of Tercica, Inc., a subsidiary of the Ipsen Group.

© 2010 Make-A-Wish Foundation of America. Make-A-Wish Foundation and the
Make-A-Wish logo are registered trademarks of the Make-A-Wish Foundation of America.

APC69GH09